25 XP   0   0   10

Biohaven Pharmaceutical Holding Co Ltd
Buy, Hold or Sell?

Let's analyse Biohaven together

PenkeI guess you are interested in Biohaven Pharmaceutical Holding Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biohaven Pharmaceutical Holding Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Biohaven Pharmaceutical Holding Co Ltd

I send you an email if I find something interesting about Biohaven Pharmaceutical Holding Co Ltd.

Quick analysis of Biohaven (30 sec.)










What can you expect buying and holding a share of Biohaven? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.24
Expected worth in 1 year
$3.88
How sure are you?
46.7%

+ What do you gain per year?

Total Gains per Share
$-1.36
Return On Investment
-3.5%

For what price can you sell your share?

Current Price per Share
$38.99
Expected price per share
$26.93 - $43.05
How sure are you?
50%

1. Valuation of Biohaven (5 min.)




Live pricePrice per Share (EOD)

$38.99

Intrinsic Value Per Share

$-68.30 - $-80.42

Total Value Per Share

$-63.05 - $-75.17

2. Growth of Biohaven (5 min.)




Is Biohaven growing?

Current yearPrevious yearGrowGrow %
How rich?$427.9m$108.7m$285.6m72.4%

How much money is Biohaven making?

Current yearPrevious yearGrowGrow %
Making money-$102m-$142.5m$40.5m39.7%
Net Profit Margin0.0%-7.9%--

How much money comes from the company's main activities?

3. Financial Health of Biohaven (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Biohaven? (5 min.)

Welcome investor! Biohaven's management wants to use your money to grow the business. In return you get a share of Biohaven.

What can you expect buying and holding a share of Biohaven?

First you should know what it really means to hold a share of Biohaven. And how you can make/lose money.

Speculation

The Price per Share of Biohaven is $38.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biohaven.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biohaven, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.24. Based on the TTM, the Book Value Change Per Share is $-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is $1.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biohaven.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.77-4.5%-1.39-3.6%-1.75-4.5%-1.67-4.3%-1.54-3.9%
Usd Book Value Change Per Share1.694.3%-0.34-0.9%1.363.5%0.300.8%0.350.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.694.3%-0.34-0.9%1.363.5%0.300.8%0.350.9%
Usd Price Per Share42.80-26.60-5.05-9.74-8.44-
Price to Earnings Ratio-6.04--4.67--0.82--1.69--1.46-
Price-to-Total Gains Ratio25.33--9.06--0.30--6.14--6.14-
Price to Book Ratio8.17-5.72-1.81-2.32-2.01-
Price-to-Total Gains Ratio25.33--9.06--0.30--6.14--6.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share38.99
Number of shares25
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.340.30
Usd Total Gains Per Share-0.340.30
Gains per Quarter (25 shares)-8.487.54
Gains per Year (25 shares)-33.9230.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-34-4403020
20-68-7806050
30-102-11209080
40-136-1460121110
50-170-1800151140
60-204-2140181170
70-237-2480211200
80-271-2820241230
90-305-3160271260
100-339-3500302290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.011.00.00.0%0.013.00.00.0%0.015.00.00.0%0.015.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.07.00.036.4%5.08.00.038.5%7.08.00.046.7%7.08.00.046.7%
Dividend per Share0.00.04.00.0%0.00.011.00.0%0.00.013.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share1.03.00.025.0%4.07.00.036.4%5.08.00.038.5%7.08.00.046.7%7.08.00.046.7%

Fundamentals of Biohaven

About Biohaven Pharmaceutical Holding Co Ltd

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Fundamental data was last updated by Penke on 2024-04-16 18:21:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Biohaven Pharmaceutical Holding Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biohaven earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-7.9%+7.9%
TTM-5Y-1,209.9%+1,209.9%
5Y-1,209.9%10Y-1,048.6%-161.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY-7.9%-279.3%+271.4%
5Y-1,209.9%-438.4%-771.5%
10Y-1,048.6%-605.5%-443.1%
1.1.2. Return on Assets

Shows how efficient Biohaven is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • -28.2% Return on Assets means that Biohaven generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is -28.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.2%TTM-21.1%-7.1%
TTM-21.1%YOY-37.3%+16.3%
TTM-21.1%5Y-27.6%+6.6%
5Y-27.6%10Y-30.5%+2.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.2%-13.5%-14.7%
TTM-21.1%-12.9%-8.2%
YOY-37.3%-11.8%-25.5%
5Y-27.6%-14.1%-13.5%
10Y-30.5%-16.0%-14.5%
1.1.3. Return on Equity

Shows how efficient Biohaven is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • -33.8% Return on Equity means Biohaven generated $-0.34 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is -33.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.8%TTM-26.9%-7.0%
TTM-26.9%YOY-45.9%+19.0%
TTM-26.9%5Y-49.7%+22.9%
5Y-49.7%10Y-48.4%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.8%-16.9%-16.9%
TTM-26.9%-16.1%-10.8%
YOY-45.9%-15.1%-30.8%
5Y-49.7%-19.9%-29.8%
10Y-48.4%-20.9%-27.5%

1.2. Operating Efficiency of Biohaven Pharmaceutical Holding Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biohaven is operating .

  • Measures how much profit Biohaven makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-5.1%+5.1%
TTM-5Y-6.8%+6.8%
5Y-6.8%10Y-5.9%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY-5.1%-288.4%+283.3%
5Y-6.8%-477.4%+470.6%
10Y-5.9%-625.6%+619.7%
1.2.2. Operating Ratio

Measures how efficient Biohaven is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.072-0.072
TTM-5Y10.759-10.759
5Y10.75910Y9.324+1.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY0.0723.783-3.711
5Y10.7595.679+5.080
10Y9.3247.894+1.430

1.3. Liquidity of Biohaven Pharmaceutical Holding Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biohaven is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.98 means the company has $7.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 7.983. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.674. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.983TTM5.674+2.309
TTM5.674YOY3.959+1.715
TTM5.6745Y4.507+1.167
5Y4.50710Y4.589-0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9833.914+4.069
TTM5.6744.220+1.454
YOY3.9595.388-1.429
5Y4.5076.045-1.538
10Y4.5896.406-1.817
1.3.2. Quick Ratio

Measures if Biohaven is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • A Quick Ratio of 9.57 means the company can pay off $9.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 9.566. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.965. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.566TTM6.965+2.601
TTM6.965YOY5.589+1.376
TTM6.9655Y5.645+1.321
5Y5.64510Y5.530+0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5663.572+5.994
TTM6.9653.998+2.967
YOY5.5895.390+0.199
5Y5.6455.969-0.324
10Y5.5306.287-0.757

1.4. Solvency of Biohaven Pharmaceutical Holding Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biohaven assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biohaven to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Biohaven assets are financed with 16.6% credit (debt) and the remaining percentage (100% - 16.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 0.166. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.220. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.166TTM0.220-0.054
TTM0.220YOY0.500-0.280
TTM0.2205Y0.560-0.339
5Y0.56010Y0.539+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1660.336-0.170
TTM0.2200.334-0.114
YOY0.5000.269+0.231
5Y0.5600.366+0.194
10Y0.5390.390+0.149
1.4.2. Debt to Equity Ratio

Measures if Biohaven is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biohaven to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.9% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The MRQ is 0.199. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.284. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.199TTM0.284-0.085
TTM0.284YOY0.213+0.072
TTM0.2845Y0.634-0.350
5Y0.63410Y0.561+0.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1990.382-0.183
TTM0.2840.396-0.112
YOY0.2130.335-0.122
5Y0.6340.434+0.200
10Y0.5610.465+0.096

2. Market Valuation of Biohaven Pharmaceutical Holding Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biohaven generates.

  • Above 15 is considered overpriced but always compare Biohaven to the Biotechnology industry mean.
  • A PE ratio of -6.04 means the investor is paying $-6.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The EOD is -5.499. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.036. Based on the earnings, the company is expensive. -2
  • The TTM is -4.673. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.499MRQ-6.036+0.537
MRQ-6.036TTM-4.673-1.363
TTM-4.673YOY-0.819-3.854
TTM-4.6735Y-1.690-2.983
5Y-1.69010Y-1.465-0.225
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.499-2.259-3.240
MRQ-6.036-2.569-3.467
TTM-4.673-2.664-2.009
YOY-0.819-4.120+3.301
5Y-1.690-6.258+4.568
10Y-1.465-6.171+4.706
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The EOD is -6.901. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.575. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.879. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.901MRQ-7.575+0.674
MRQ-7.575TTM-6.879-0.696
TTM-6.879YOY-1.257-5.622
TTM-6.8795Y-2.503-4.376
5Y-2.50310Y-2.170-0.334
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.901-2.924-3.977
MRQ-7.575-3.246-4.329
TTM-6.879-3.488-3.391
YOY-1.257-5.620+4.363
5Y-2.503-8.315+5.812
10Y-2.170-8.826+6.656
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biohaven is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 8.17 means the investor is paying $8.17 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Biohaven Pharmaceutical Holding Co Ltd:

  • The EOD is 7.440. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.167. Based on the equity, the company is overpriced. -1
  • The TTM is 5.724. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.440MRQ8.167-0.727
MRQ8.167TTM5.724+2.442
TTM5.724YOY1.809+3.915
TTM5.7245Y2.318+3.406
5Y2.31810Y2.009+0.309
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.4401.851+5.589
MRQ8.1672.090+6.077
TTM5.7242.095+3.629
YOY1.8092.844-1.035
5Y2.3183.466-1.148
10Y2.0093.815-1.806
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Biohaven Pharmaceutical Holding Co Ltd.

3.1. Institutions holding Biohaven Pharmaceutical Holding Co Ltd

Institutions are holding 89.892% of the shares of Biohaven Pharmaceutical Holding Co Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Stifel Financial Corp7.63150.335362258114560627.9044
2023-12-31HHG PLC7.23380.1507590134357576210.8113
2023-12-31BlackRock Inc7.06390.00635762738152176135.8823
2023-12-31Suvretta Capital Management, LLC5.60538.8486457283656723614.1611
2023-12-31State Street Corporation4.74480.00813870839-90668-2.2887
2023-12-31T. Rowe Price Associates, Inc.3.8420.018313432379118133.7658
2023-12-31RP Management, LLC3.599584.5077293650700
2023-12-31Adage Capital Partners Gp LLC2.47690.179202064477856962.6829
2023-09-30Holocene Advisors, LP2.41450.22431969752-94236-4.5657
2023-12-31FMR Inc2.36450.00631928992-1330141-40.8127
2023-12-31Goldman Sachs Group Inc2.31850.007318914301017565116.4442
2023-12-31Perceptive Advisors LLC2.11451.6481725047973227129.4495
2023-12-31Vanguard Group Inc2.03250.0016165815122916816.0371
2023-12-31Armistice Capital, LLC1.83870.87641500000-536000-26.3261
2023-12-31Geode Capital Management, LLC1.74850.0064142644626325622.6322
2023-12-31Avidity Partners Management LP1.40761.79111148308-137092-10.6653
2023-12-31Bellevue Group AG1.31770.7038107500010750000
2023-09-30Point72 Asset Management, L.P.1.2570.07781025495-145303-12.4106
2023-12-31Farallon Capital Management, L.L.C.0.91930.159375000000
2023-12-31Woodline Partners LP0.91090.345974311520704238.622
Total 62.841999.901951266777+6122389+11.9%

3.2. Funds holding Biohaven Pharmaceutical Holding Co Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28iShares Russell 2000 ETF2.05390.1401167721763890.3824
2024-02-29Fidelity Select Biotechnology1.95111.56011593310-144100-8.294
2023-12-31T. Rowe Price Health Sciences1.93910.4607158347715834770
2024-03-31SPDR® S&P Biotech ETF1.62260.9545132507370720.5366
2023-12-31Janus Henderson Global Life Sciences1.38370.98731129967-249152-18.066
2023-12-31Janus Henderson Global Life Sciences D1.38370.98271129967-249152-18.066
2023-12-31Janus Henderson Triton D1.35270.6933110459711045970
2023-12-31Janus Henderson US SMID Cap Growth1.35270.6962110459711045970
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.17740.0454961484-860-0.0894
2023-12-31Janus Henderson US Small Cap Growth1.07261.229887587800
2023-12-31Janus Henderson Venture D1.07261.221587587800
2024-02-29Janus Henderson Glb Life Scn I2 USD1.05871.046186457674510.8693
2023-12-31Janus Selection Global Life Science AUSD1.03160.975842403-219660-20.6824
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.92920.416875876615091624.8278
2023-12-31American Funds SMALLCAP World A0.91830.044674988100
2023-12-31HBM Healthcare Investments AG Ord0.86281.5103704555454545181.8107
2024-01-31Fidelity Small Cap Index0.84730.1241691922114301.6797
2024-03-28iShares Russell 2000 Value ETF0.78770.2805643249-408-0.0634
2024-03-28iShares Biotechnology ETF0.63110.3694515402-1363-0.2638
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.51070.05274170667000.1681
Total 23.939513.791119549265+3566479+18.2%

3.3. Insider Transactions

Insiders are holding 13.633% of the shares of Biohaven Pharmaceutical Holding Co Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-29Irina AntonijevicSELL1100041.79
2023-10-05Matthew ButenBUY2272722
2023-10-05Vlad CoricBUY11363722
2023-10-04Gregory BaileyBUY1781722.57
2023-08-30John W ChildsBUY5000018.44
2023-08-04John W ChildsBUY10000019.78

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Biohaven Pharmaceutical Holding Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.690-0.339+120%1.360+24%0.302+460%0.349+384%
Book Value Per Share--5.2414.829+9%1.331+294%1.485+253%1.392+277%
Current Ratio--7.9835.674+41%3.959+102%4.507+77%4.589+74%
Debt To Asset Ratio--0.1660.220-25%0.500-67%0.560-70%0.539-69%
Debt To Equity Ratio--0.1990.284-30%0.213-6%0.634-69%0.561-65%
Dividend Per Share----0%-0%-0%-0%
Eps---1.773-1.385-22%-1.746-2%-1.673-6%-1.535-13%
Free Cash Flow Per Share---1.413-1.025-27%-1.037-27%-1.090-23%-1.018-28%
Free Cash Flow To Equity Per Share--1.160-0.484+142%1.313-12%0.525+121%0.459+153%
Gross Profit Margin--0.9930.9980%1.000-1%0.999-1%1.000-1%
Intrinsic Value_10Y_max---80.415--------
Intrinsic Value_10Y_min---68.295--------
Intrinsic Value_1Y_max---4.819--------
Intrinsic Value_1Y_min---4.732--------
Intrinsic Value_3Y_max---16.949--------
Intrinsic Value_3Y_min---16.131--------
Intrinsic Value_5Y_max---32.054--------
Intrinsic Value_5Y_min---29.539--------
Market Cap3183982040.960-10%3495112371.2002171991852.640+61%411982287.680+748%795068966.252+340%689059770.752+407%
Net Profit Margin----0%-0.0790%-12.0990%-10.4860%
Operating Margin----0%-0.0510%-0.0680%-0.0590%
Operating Ratio----0%0.072-100%10.759-100%9.324-100%
Pb Ratio7.440-10%8.1675.724+43%1.809+351%2.318+252%2.009+307%
Pe Ratio-5.499+9%-6.036-4.673-23%-0.819-86%-1.690-72%-1.465-76%
Price Per Share38.990-10%42.80026.598+61%5.045+748%9.736+340%8.438+407%
Price To Free Cash Flow Ratio-6.901+9%-7.575-6.879-9%-1.257-83%-2.503-67%-2.170-71%
Price To Total Gains Ratio23.078-10%25.333-9.065+136%-0.295+101%-6.142+124%-6.142+124%
Quick Ratio--9.5666.965+37%5.589+71%5.645+69%5.530+73%
Return On Assets---0.282-0.211-25%-0.373+32%-0.276-2%-0.305+8%
Return On Equity---0.338-0.269-21%-0.459+36%-0.497+47%-0.484+43%
Total Gains Per Share--1.690-0.339+120%1.360+24%0.302+460%0.349+384%
Usd Book Value--427975000.000394373500.000+9%108700500.000+294%121276461.538+253%113651200.000+277%
Usd Book Value Change Per Share--1.690-0.339+120%1.360+24%0.302+460%0.349+384%
Usd Book Value Per Share--5.2414.829+9%1.331+294%1.485+253%1.392+277%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.773-1.385-22%-1.746-2%-1.673-6%-1.535-13%
Usd Free Cash Flow---115351000.000-83693250.000-27%-84690750.000-27%-89004692.308-23%-83108266.667-28%
Usd Free Cash Flow Per Share---1.413-1.025-27%-1.037-27%-1.090-23%-1.018-28%
Usd Free Cash Flow To Equity Per Share--1.160-0.484+142%1.313-12%0.525+121%0.459+153%
Usd Market Cap3183982040.960-10%3495112371.2002171991852.640+61%411982287.680+748%795068966.252+340%689059770.752+407%
Usd Price Per Share38.990-10%42.80026.598+61%5.045+748%9.736+340%8.438+407%
Usd Profit---144756000.000-102042000.000-30%-142569750.000-2%-121915923.077-16%-112608133.333-22%
Usd Revenue----0%79713000.000-100%53044538.462-100%45971933.333-100%
Usd Total Gains Per Share--1.690-0.339+120%1.360+24%0.302+460%0.349+384%
 EOD+2 -6MRQTTM+19 -11YOY+20 -125Y+21 -1110Y+22 -10

4.2. Fundamental Score

Let's check the fundamental score of Biohaven Pharmaceutical Holding Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.499
Price to Book Ratio (EOD)Between0-17.440
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.566
Current Ratio (MRQ)Greater than17.983
Debt to Asset Ratio (MRQ)Less than10.166
Debt to Equity Ratio (MRQ)Less than10.199
Return on Equity (MRQ)Greater than0.15-0.338
Return on Assets (MRQ)Greater than0.05-0.282
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Biohaven Pharmaceutical Holding Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.441
Ma 20Greater thanMa 5050.690
Ma 50Greater thanMa 10051.665
Ma 100Greater thanMa 20046.324
OpenGreater thanClose42.360
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  284-118166-14620138158-223-65



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets513,212
Total Liabilities85,237
Total Stockholder Equity427,975
 As reported
Total Liabilities 85,237
Total Stockholder Equity+ 427,975
Total Assets = 513,212

Assets

Total Assets513,212
Total Current Assets442,446
Long-term Assets70,766
Total Current Assets
Cash And Cash Equivalents 249,720
Short-term Investments 133,417
Net Receivables 13,648
Other Current Assets 45,661
Total Current Assets  (as reported)442,446
Total Current Assets  (calculated)442,446
+/-0
Long-term Assets
Property Plant Equipment 48,576
Goodwill 1,390
Intangible Assets 18,400
Long-term Assets Other 2,400
Long-term Assets  (as reported)70,766
Long-term Assets  (calculated)70,766
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities55,423
Long-term Liabilities29,814
Total Stockholder Equity427,975
Total Current Liabilities
Short-term Debt 3,308
Accounts payable 15,577
Other Current Liabilities 36,538
Total Current Liabilities  (as reported)55,423
Total Current Liabilities  (calculated)55,423
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt27,569
Long-term Liabilities Other 2,245
Long-term Liabilities  (as reported)29,814
Long-term Liabilities  (calculated)29,814
+/- 0
Total Stockholder Equity
Common Stock887,528
Retained Earnings -499,292
Accumulated Other Comprehensive Income -65
Other Stockholders Equity 39,804
Total Stockholder Equity (as reported)427,975
Total Stockholder Equity (calculated)427,975
+/-0
Other
Capital Stock887,528
Cash and Short Term Investments 383,137
Common Stock Shares Outstanding 79,930
Liabilities and Stockholders Equity 513,212
Net Debt -218,843
Net Invested Capital 427,975
Net Working Capital 387,023
Property Plant and Equipment Gross 56,859
Short Long Term Debt Total 30,877



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-31
> Total Assets 
60,191
214,255
184,670
126,135
239,290
195,091
290,012
245,080
490,908
439,087
344,264
532,669
424,255
782,015
686,975
1,003,159
845,893
1,131,195
142,061
1,371,717
332,810
135,646
661,783
618,521
506,736
382,736
513,212
513,212382,736506,736618,521661,783135,646332,8101,371,717142,0611,131,195845,8931,003,159686,975782,015424,255532,669344,264439,087490,908245,080290,012195,091239,290126,135184,670214,25560,191
   > Total Current Assets 
53,169
208,616
179,503
114,673
227,602
182,980
272,339
227,373
474,352
423,170
328,281
474,446
362,562
708,285
603,406
900,696
666,580
944,381
94,823
1,171,085
281,341
80,550
586,968
544,476
434,118
310,570
442,446
442,446310,570434,118544,476586,96880,550281,3411,171,08594,823944,381666,580900,696603,406708,285362,562474,446328,281423,170474,352227,373272,339182,980227,602114,673179,503208,61653,169
       Cash And Cash Equivalents 
52,286
204,290
175,754
104,206
217,452
168,185
264,249
217,407
465,739
416,574
316,727
428,239
261,061
316,231
132,149
464,714
306,267
501,409
76,057
169,065
257,799
50,668
204,877
125,031
147,612
111,697
249,720
249,720111,697147,612125,031204,87750,668257,799169,06576,057501,409306,267464,714132,149316,231261,061428,239316,727416,574465,739217,407264,249168,185217,452104,206175,754204,29052,286
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
229,983
223,185
101,547
59,840
19,031
192,648
433,410
317,679
0
260,464
262,998
187,503
128,899
133,417
133,417128,899187,503262,998260,4640317,679433,410192,64819,03159,840101,547223,185229,9830000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
4,337
44,796
79,522
120,111
156,769
168,637
252,952
9,911
328,342
8,097
11,340
46,139
43,830
8,656
13,073
13,648
13,64813,0738,65643,83046,13911,3408,097328,3429,911252,952168,637156,769120,11179,52244,7964,33700000000000
       Other Current Assets 
883
4,326
3,749
10,467
10,150
14,795
8,090
9,966
8,613
6,596
11,554
37,288
47,735
62,418
88,398
119,337
67,778
96,125
2,121
148,987
976
632
19,331
24,669
22,278
22,937
45,661
45,66122,93722,27824,66919,331632976148,9872,12196,12567,778119,33788,39862,41847,73537,28811,5546,5968,6139,9668,09014,79510,15010,4673,7494,326883
   > Long-term Assets 
7,022
5,639
5,167
11,462
11,688
12,111
17,673
17,707
16,556
15,917
15,983
58,223
61,693
73,730
83,569
102,463
179,313
186,814
47,238
200,632
51,470
55,096
74,815
74,045
72,618
72,166
70,766
70,76672,16672,61874,04574,81555,09651,470200,63247,238186,814179,313102,46383,56973,73061,69358,22315,98315,91716,55617,70717,67312,11111,68811,4625,1675,6397,022
       Property Plant Equipment 
43
92
267
2,936
3,792
4,891
6,248
7,157
7,433
7,460
8,152
8,933
8,979
8,802
9,340
11,258
10,885
10,409
18,232
14,534
20,660
24,338
52,440
51,526
50,477
49,999
48,576
48,57649,99950,47751,52652,44024,33820,66014,53418,23210,40910,88511,2589,3408,8028,9798,9338,1527,4607,4337,1576,2484,8913,7922,9362679243
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,390
0
1,390
1,390
1,390
1,390
1,390
1,390
1,390
1,3901,3901,3901,3901,3901,3901,39001,390000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,000
0
10,000
10,000
0
0
0
0
0
0000010,00010,00006,000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
41,259
40,535
39,811
39,087
58,226
57,501
56,968
18,400
55,910
18,400
18,400
18,400
18,400
18,400
18,400
18,400
18,40018,40018,40018,40018,40018,40018,40055,91018,40056,96857,50158,22639,08739,81140,53541,25900000000000
       Long-term Assets Other 
6,970
5,538
4,900
8,526
7,896
7,220
11,425
10,550
9,123
8,457
7,831
8,031
12,179
25,117
35,142
32,979
110,927
119,437
3,216
130,188
1,020
968
2,585
2,729
2,351
2,377
2,400
2,4002,3772,3512,7292,5859681,020130,1883,216119,437110,92732,97935,14225,11712,1798,0317,8318,4579,12310,55011,4257,2207,8968,5264,9005,5386,970
> Total Liabilities 
39,833
21,403
28,477
18,319
120,460
129,278
139,092
148,069
304,167
320,111
351,688
410,711
459,721
935,833
1,019,164
1,221,314
1,242,489
1,662,402
47,370
1,838,130
70,582
35,430
123,012
146,263
119,481
92,730
85,237
85,23792,730119,481146,263123,01235,43070,5821,838,13047,3701,662,4021,242,4891,221,3141,019,164935,833459,721410,711351,688320,111304,167148,069139,092129,278120,46018,31928,47721,40339,833
   > Total Current Liabilities 
15,442
17,521
22,113
16,865
12,755
15,264
19,534
23,693
44,669
47,206
66,173
122,098
166,417
217,118
276,760
395,791
399,132
462,276
41,935
576,114
63,210
28,435
90,021
114,006
87,847
62,177
55,423
55,42362,17787,847114,00690,02128,43563,210576,11441,935462,276399,132395,791276,760217,118166,417122,09866,17347,20644,66923,69319,53415,26412,75516,86522,11317,52115,442
       Short-term Debt 
4,489
4,785
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
62,500
0
0
1,134
38,231
0
0
3,281
3,308
3,3083,2810038,2311,1340062,50000000000000000004,7854,489
       Accounts payable 
4,022
5,986
8,753
9,051
4,027
4,658
10,752
8,210
13,502
11,562
14,071
29,703
17,044
43,976
48,476
64,571
60,002
49,437
4,775
56,202
3,737
4,731
10,703
14,456
12,039
9,515
15,577
15,5779,51512,03914,45610,7034,7313,73756,2024,77549,43760,00264,57148,47643,97617,04429,70314,07111,56213,5028,21010,7524,6584,0279,0518,7535,9864,022
       Other Current Liabilities 
6,931
6,750
13,360
7,814
8,728
10,606
8,782
15,483
31,167
35,644
52,102
92,395
149,373
173,142
228,284
331,220
339,130
412,839
37,160
519,912
59,473
23,704
79,318
92,194
75,808
52,662
36,538
36,53852,66275,80892,19479,31823,70459,473519,91237,160412,839339,130331,220228,284173,142149,37392,39552,10235,64431,16715,4838,78210,6068,7287,81413,3606,7506,931
   > Long-term Liabilities 
24,391
3,882
6,364
1,454
107,705
114,014
119,558
124,376
259,498
272,905
285,515
288,613
293,304
718,715
742,404
825,523
843,357
1,200,126
5,435
1,262,016
7,372
6,995
32,991
32,257
31,634
30,553
29,814
29,81430,55331,63432,25732,9916,9957,3721,262,0165,4351,200,126843,357825,523742,404718,715293,304288,613285,515272,905259,498124,376119,558114,014107,7051,4546,3643,88224,391
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
626,720
0
0
0
0
0
0
0
0
00000000626,720000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60,000
0
0
0
0
0
0
0
0
0000000060,000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,638
2,638
3,020
3,020
2,925
2,410
0
0
2,267
0
02,267002,4102,9253,0203,0202,6382,63800000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,110
0
0
0
0
0
0
0
0
0000000013,110000000000000000000
> Total Stockholder Equity
-53,542
192,852
156,193
107,816
118,830
65,813
150,920
97,011
186,741
118,976
-7,424
121,958
-35,466
-212,379
-390,370
-275,976
-453,877
-587,976
34,691
-462,286
262,228
100,216
538,771
472,258
387,255
290,006
427,975
427,975290,006387,255472,258538,771100,216262,228-462,28634,691-587,976-453,877-275,976-390,370-212,379-35,466121,958-7,424118,976186,74197,011150,92065,813118,830107,816156,193192,852-53,542
   Common Stock
20,296
310,635
310,635
367,730
413,225
418,273
554,384
556,345
844,966
874,589
881,426
1,175,139
1,199,005
1,205,384
1,249,547
1,604,021
1,618,194
1,633,462
1,676,792
2,112,686
262,228
100,216
615,742
616,246
617,510
618,761
887,528
887,528618,761617,510616,246615,742100,216262,2282,112,6861,676,7921,633,4621,618,1941,604,0211,249,5471,205,3841,199,0051,175,139881,426874,589844,966556,345554,384418,273413,225367,730310,635310,63520,296
   Retained Earnings -499,292-354,536-251,962-161,616-91,1240-3,143,541-2,702,154-2,585,755-2,386,572-2,214,756-2,004,137-1,739,169-1,521,433-1,326,244-1,145,310-972,373-823,109-716,942-505,872-443,568-388,818-327,377-288,108-175,564-132,649-94,209
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
169,656
0
0
0
0
0
0
0
0
00000000169,656000000000000000000
   Treasury Stock000000000000000000000000000
   Other Stockholders Equity 
20,371
14,866
21,122
28,194
32,982
36,358
40,104
46,538
58,717
67,496
83,523
92,129
91,773
103,419
98,938
123,731
142,405
165,052
943,654
129,580
3,149,352
100,216
13,869
17,462
21,687
25,623
39,804
39,80425,62321,68717,46213,869100,2163,149,352129,580943,654165,052142,405123,73198,938103,41991,77392,12983,52367,49658,71746,53840,10436,35832,98228,19421,12214,86620,371



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,369
Gross Profit-3,369-3,369
 
Operating Income (+$)
Gross Profit-3,369
Operating Expense-432,682
Operating Income-436,051-436,051
 
Operating Expense (+$)
Research Development373,281
Selling General Administrative62,770
Selling And Marketing Expenses0
Operating Expense432,682436,051
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-436,051
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-409,551-462,551
EBIT - interestExpense = -436,051
-409,551
-408,168
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-436,051-409,551
Earnings Before Interest and Taxes (EBITDA)-432,682
 
After tax Income (+$)
Income Before Tax-409,551
Tax Provision--1,383
Net Income From Continuing Ops-408,168-408,168
Net Income-408,168
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses436,051
Total Other Income/Expenses Net26,5000
 

Technical Analysis of Biohaven
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biohaven. The general trend of Biohaven is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biohaven's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biohaven Pharmaceutical Holding Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 39.84 < 42.02 < 43.05.

The bearish price targets are: 32.08 > 31.21 > 26.93.

Tweet this
Biohaven Pharmaceutical Holding Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biohaven Pharmaceutical Holding Co Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biohaven Pharmaceutical Holding Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biohaven Pharmaceutical Holding Co Ltd. The current macd is -2.88485268.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biohaven price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biohaven. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biohaven price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biohaven Pharmaceutical Holding Co Ltd. The current adx is 23.34.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biohaven shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biohaven Pharmaceutical Holding Co Ltd. The current sar is 48.74.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biohaven Pharmaceutical Holding Co Ltd. The current rsi is 25.44. The current phase is Oversold in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bull market: Short-term excessive selling, potential for rebound. Consider buying at a perceived discount, watch for reversal signs. +1
  • Trending down: The RSI is trending down. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Relative Strength Index (RSI) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biohaven Pharmaceutical Holding Co Ltd. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biohaven price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Stochastic Oscillator ChartBiohaven Pharmaceutical Holding Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biohaven Pharmaceutical Holding Co Ltd. The current cci is -193.25301737.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Commodity Channel Index (CCI) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biohaven Pharmaceutical Holding Co Ltd. The current cmo is -63.53615029.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Chande Momentum Oscillator (CMO) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biohaven Pharmaceutical Holding Co Ltd. The current willr is -92.37990061.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Biohaven Pharmaceutical Holding Co Ltd Daily Williams %R ChartBiohaven Pharmaceutical Holding Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Biohaven Pharmaceutical Holding Co Ltd.

Biohaven Pharmaceutical Holding Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biohaven Pharmaceutical Holding Co Ltd. The current atr is 3.39545023.

Biohaven Pharmaceutical Holding Co Ltd Daily Average True Range (ATR) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biohaven Pharmaceutical Holding Co Ltd. The current obv is 77,208,764.

Biohaven Pharmaceutical Holding Co Ltd Daily On-Balance Volume (OBV) ChartBiohaven Pharmaceutical Holding Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biohaven Pharmaceutical Holding Co Ltd. The current mfi is 26.84.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Biohaven Pharmaceutical Holding Co Ltd Daily Money Flow Index (MFI) ChartBiohaven Pharmaceutical Holding Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biohaven Pharmaceutical Holding Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Biohaven Pharmaceutical Holding Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biohaven Pharmaceutical Holding Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5025.441
Ma 20Greater thanMa 5050.690
Ma 50Greater thanMa 10051.665
Ma 100Greater thanMa 20046.324
OpenGreater thanClose42.360
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biohaven with someone you think should read this too:
  • Are you bullish or bearish on Biohaven? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biohaven? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biohaven Pharmaceutical Holding Co Ltd

I send you an email if I find something interesting about Biohaven Pharmaceutical Holding Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Biohaven Pharmaceutical Holding Co Ltd.

Receive notifications about Biohaven Pharmaceutical Holding Co Ltd in your mailbox!